4D Molecular Therapeutics, Inc.
FDMT
$14.22
-$0.41-2.80%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 25,106.67% | 21,664.29% | 8,508,900.00% | 2,900.00% | 200.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25,106.67% | 21,664.29% | 8,508,900.00% | 2,900.00% | 200.00% |
| Cost of Revenue | 42.40% | 59.66% | 33.47% | 22.75% | 50.51% |
| Gross Profit | -34.56% | -52.23% | 164.02% | -22.52% | -50.48% |
| SG&A Expenses | 8.72% | -9.66% | -2.03% | -6.43% | 8.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.87% | 42.94% | 25.23% | 15.53% | 40.06% |
| Operating Income | -29.55% | -37.30% | 126.40% | -15.36% | -40.04% |
| Income Before Tax | -33.44% | -43.33% | 139.05% | -29.73% | -56.38% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.44% | -43.33% | 139.05% | -29.73% | -56.38% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.44% | -43.33% | 139.05% | -29.73% | -56.38% |
| EBIT | -29.55% | -37.30% | 126.40% | -15.36% | -40.04% |
| EBITDA | -29.95% | -37.63% | 129.14% | -15.58% | -41.27% |
| EPS Basic | -6.20% | -17.38% | 134.00% | -28.41% | -54.56% |
| Normalized Basic EPS | -6.20% | -17.38% | 134.16% | -23.44% | -54.55% |
| EPS Diluted | -6.20% | -17.38% | 134.00% | -28.41% | -54.56% |
| Normalized Diluted EPS | -6.20% | -17.38% | 134.16% | -23.44% | -54.55% |
| Average Basic Shares Outstanding | 25.65% | 22.10% | 14.88% | 1.03% | 1.17% |
| Average Diluted Shares Outstanding | 25.65% | 22.10% | 14.88% | 1.03% | 1.17% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |